Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07536282Phase 1Not Yet Recruiting

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Role: lead

NCT07175662Phase 2Recruiting

Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

Role: lead

NCT07047989Phase 1Recruiting

NWRD09 for HPV-16 Related Cervical HSIL

Role: lead

All 3 trials loaded